Brief: Combigene Discontinues Preclinical Development Of Lipodystrophy Project CGT2

Larkberget AB

01/02/2024 08:15

Feb 1 (Reuters) - Combigene AB  COMBI.ST :
    * DISCONTINUES PRECLINICAL DEVELOPMENT OF LIPODYSTROPHY
PROJECT
CGT2
    * THERE IS NOT ENOUGH CONVINCING DATA TO JUSTIFY CONTINUED
COSTLY
PRECLINICAL DEVELOPMENT
    * RIGHTS TO PROJECT WILL REVERT TO LIPIGON NO LATER THAN
AUGUST 5,
2024

Source text for Eikon:  ID:nMFN2P6RST 
Further company coverage:  COMBI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))